Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -4 of 4 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 8/15/2007 First Published: 2/1/2001


1.		Phase II Study of Karenitecin in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				CLB-30004 NCT00010218, CALGB-30004

Last Modified: 8/5/2008 First Published: 1/26/2003


2.		Phase II Study of Karenitecin as Third-Line Treatment in Patients With Persistent or Recurrent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Any age				NCI				GOG-0186D BIONUM-KTN22307, NCT00054119


3.		Study of Karenitecin (BNP1350) in Patients With Brain Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				KTN20405 NCT00062478

Last Modified: 10/9/2006 First Published: 4/1/2001


4.		Phase I Study of Karenitecin in Patients With Recurrent Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				NABTT-2006 JHOC-NABTT-2006, NCT00014521

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute